Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Breast Neoplasms 5Leukemia 4Recurrence 3Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lung Neoplasms 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioblastoma 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Spinal Cord Neoplasms 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Prostatic Neoplasms 1Prostate Cancer Recurrent 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Optic Nerve Glioma 1

Interventions

Temozolomide 69Radiotherapy 30Bevacizumab 24Carboplatin 13pembrolizumab 12Radiation 11Carmustine 8Irinotecan 7temsirolimus 6Surgical Procedures, Operative 6Radiosurgery 6Erlotinib Hydrochloride 6atezolizumab 5Vorinostat 5Sirolimus 5Radiotherapy, Intensity-Modulated 5Nivolumab 5Lomustine 5Everolimus 5fludarabine 4Radiotherapy, Conformal 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Aminolevulinic Acid 4tipifarnib 3Sorafenib 3Paclitaxel 3IL13-PE38 3Granulocyte-Macrophage Colony-Stimulating Factor 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Glioblastoma × Dasatinib × Clear all
NCT00869401 2020-02-13

Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Alliance for Clinical Trials in Oncology

Phase 1/2 Completed
217 enrolled 12 charts
CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00948389 2012-08-31

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Bristol-Myers Squibb

Phase 1/2 Terminated
28 enrolled 16 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡